Arctic Bioscience – Invitation to presentation of Q4 2023 operational update


Arctic Bioscience will publish a Q4 2023 operational update and preliminary full year 2023 financial results on Friday 1st of March, at 08:00 CET.

The same day at 11:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience.

Webcast details:

Date: Friday 1st of March 2024

Time: 11:00 CET

Format: Webcast and Q&A

Language: English

The presentation can be accessed through the Company’s website, or with the link below:


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug


Phone: +47 920 84 601


Jone R. Slinning


Mobile: +47 948 75 469


About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.

The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.

Documents & Links